ClinicalTrials.gg
CompletedNCT00710749Updated Nov 11, 2021Results posted

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

An interventional study of Disposable device and Digital device in Bladder Outlet Obstruction and Lower Urinary Tract Symptoms, sponsored by Wellspect HealthCare. Completed at 4 sites in 4 countries. Open to male participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-11-11.

Sponsored by Wellspect HealthCare (part of Dentsply Sirona) · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years to 85 Years
Sex
Male
01

Study summary

Crossover comparison of different flow meters with a digital home flow meter as a reference. Main hypothesis: Reapeated home flow measurements with a disposable device will provide a better understanding of the patients urinary flow than a single measurement performed in the clinic.

02

Conditions studied

  • Bladder Outlet Obstruction
  • Lower Urinary Tract Symptoms

Keywords

  • Lower urinary tract symptoms leading to lower flow rates
03

In context

Urinary Bladder Neck Obstruction

46 studies on the registry are indexed under Urinary Bladder Neck Obstruction; 10 are open to participants now.

This study's enrollment of 60 is below the median of 88 across 30 interventional studies indexed under Urinary Bladder Neck Obstruction.

Browse Urinary Bladder Neck Obstruction studies →

Lead sponsor

Wellspect HealthCare is the lead sponsor of 23 studies on the registry; 1 is open to participants now.

First submitted before Wellspect HealthCare became part of Dentsply Sirona.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 85 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of
  • Males aged 45-85 years
  • >60% of the voiding volume is above 100 ml per voiding verified by a urinary diary
  • Able to read write and understand given instructions

Exclusion criteria

Exclusion Criteria:

  • Patients practicing CIC
  • Ongoing symptomatic UTI
  • Known Neurological Disease that is affecting the bladder function
  • Known past or present alcohol or drug abuse
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site)
  • Previous enrolment or randomisation of treatment in the present study.
  • Suspected poor compliance based on less than 80 % compliance to voiding diary
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
  • On alpha-blocker or 5-alpha reductase inhibitor treatment, treatment started less than 2 months prior to enrolment
  • Clinic flow below 100 ml
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Disposable device first, then Digital device

    Device: Disposable device · Device: Digital device · Device: Clinic flow measurement

  • Experimental
    Digital device first, then Disposable device

    Device: Disposable device · Device: Digital device · Device: Clinic flow measurement

Interventions

  • DeviceDisposable device

    Disposable urine flow meter

  • DeviceDigital device

    Digital urine flowmeter

  • DeviceClinic flow measurement

    Clinic gold standard flow measurement

06

What researchers measure

Primary outcomes

  1. Mean Urine Flow Rate

    Measurements with a disposable device and the current clinic gold standard measurement were compared to test the hypothesis that three repeated measurements with the disposable device was as accurate as one clinic flow measurement. A digital device was used as a reference of the most exact way to evaluate each patient's individual flow.

    Time frame: At every voiding event during approximately one week.

07

Results

Posted Jun 23, 2011

Participant flow

Clinic Baseline Recording
Participant flow — Clinic Baseline Recording
MilestoneDisposable Device First, Then Digital DeviceDigital Device First, Then Disposable Device
Started3030
Completed3030
Not completed00
First Intervention
Participant flow — First Intervention
MilestoneDisposable Device First, Then Digital DeviceDigital Device First, Then Disposable Device
Started3030
Completed2930
Not completed10
Withdrew: Withdrawal by subject10
Second Intervention
Participant flow — Second Intervention
MilestoneDisposable Device First, Then Digital DeviceDigital Device First, Then Disposable Device
Started2930
Completed2930
Not completed00

Outcome measures

PrimaryMean Urine Flow Rate

Measurements with a disposable device and the current clinic gold standard measurement were compared to test the hypothesis that three repeated measurements with the disposable device was as accurate as one clinic flow measurement. A digital device was used as a reference of the most exact way to evaluate each patient's individual flow.

Time frame:
At every voiding event during approximately one week.
Reported as:
Mean · ml/s
Mean Urine Flow Rate
ml/sDisposable DeviceClinicDigital Device
Mean Urine Flow Rate12 ± 413 ± 716 ± 8
Statistical analysis
  • Disposable Device vs Clinic · Wilcoxon signed rank test · p = 0.44
  • Clinic vs Digital Device · Wilcoxon signed rank test · p = 0.0001
  • Disposable Device vs Digital Device · Wilcoxon signed rank test · p = <0.0001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Disposable Device—0/60 (0%)0/60 (0%)
Clinic—0/60 (0%)0/60 (0%)
Digital Device—0/60 (0%)0/60 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean66 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male60
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United States2
Poland16
Netherlands13
United Kingdom29
08

Study locations

4 sites
  • David Geffen school of Medicine at UCLA, Department of Urology
    Los Angeles, California 90095-1738, United States
  • UMC ST Radboud Nijmegen, Department of Urology
    Nijmegen, 6500 HB, Netherlands
  • Klinika Urology, Akademi Medycznej
    Warsaw, 02005, Poland
  • Clinical Research Unit, Morriston Hospital, Swansea NHS Trust
    Swansea, SA6 6NL, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2008
First posted
Jul 4, 2008
Start
Jul 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jun 23, 2011
Last update
Nov 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00710749
Responsible party
Sponsor
First posted
Jul 4, 2008
Start date
Jul 2008
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jun 23, 2011
Last update
Nov 11, 2021

Study contacts

Magnus Jacobsson, Prof.
study chair · Dentsply Sirona Implants and Consumables

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion